<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Med</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Med</journal-id><journal-id journal-id-type="pmc-domain-id">2745</journal-id><journal-id journal-id-type="pmc-domain">jclinmed</journal-id><journal-id journal-id-type="publisher-id">jcm</journal-id><journal-title-group><journal-title>Journal of Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2077-0383</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11546520</article-id><article-id pub-id-type="pmcid-ver">PMC11546520.1</article-id><article-id pub-id-type="pmcaid">11546520</article-id><article-id pub-id-type="pmcaiid">11546520</article-id><article-id pub-id-type="pmid">39518706</article-id><article-id pub-id-type="doi">10.3390/jcm13216568</article-id><article-id pub-id-type="publisher-id">jcm-13-06568</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Real-World Clinical Outcomes of Neoadjuvant Platinum-Based Chemotherapy with Nivolumab in Non-Small Cell Lung Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7570-4550</contrib-id><name name-style="western"><surname>Shalata</surname><given-names initials="W">Walid</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-jcm-13-06568" ref-type="aff">1</xref><xref rid="af2-jcm-13-06568" ref-type="aff">2</xref><xref rid="c1-jcm-13-06568" ref-type="corresp">*</xref><xref rid="fn1-jcm-13-06568" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Daher</surname><given-names initials="S">Sameh</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af3-jcm-13-06568" ref-type="aff">3</xref><xref rid="fn1-jcm-13-06568" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Maimon Rabinovitch</surname><given-names initials="N">Natali</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af4-jcm-13-06568" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shamai</surname><given-names initials="S">Sivan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="af5-jcm-13-06568" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4956-9364</contrib-id><name name-style="western"><surname>Kian</surname><given-names initials="W">Waleed</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af6-jcm-13-06568" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4123-1107</contrib-id><name name-style="western"><surname>Turgeman</surname><given-names initials="I">Ilit</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af7-jcm-13-06568" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dudnik</surname><given-names initials="Y">Yulia</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="af1-jcm-13-06568" ref-type="aff">1</xref><xref rid="af2-jcm-13-06568" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kazareen</surname><given-names initials="O">Olga</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af8-jcm-13-06568" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rovitsky</surname><given-names initials="Y">Yulia</given-names></name><xref rid="af7-jcm-13-06568" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sabo</surname><given-names initials="E">Edmond</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="af9-jcm-13-06568" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Faber</surname><given-names initials="DL">Dan Levy</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="af10-jcm-13-06568" ref-type="aff">10</xref><xref rid="af11-jcm-13-06568" ref-type="aff">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Galili</surname><given-names initials="R">Ronen</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af10-jcm-13-06568" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5304-7425</contrib-id><name name-style="western"><surname>Wiesel</surname><given-names initials="O">Ory</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="af12-jcm-13-06568" ref-type="aff">12</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Baranovsky</surname><given-names initials="K">Konstantin</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="af10-jcm-13-06568" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3330-2959</contrib-id><name name-style="western"><surname>Agbarya</surname><given-names initials="A">Abed</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af11-jcm-13-06568" ref-type="aff">11</xref><xref rid="af13-jcm-13-06568" ref-type="aff">13</xref><xref rid="c1-jcm-13-06568" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Dragonieri</surname><given-names initials="S">Silvano</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Tanvetyanon</surname><given-names initials="T">Tawee</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-jcm-13-06568"><label>1</label>The Legacy Heritage Cancer Center, Dr. Larry Norton Institute, Soroka Medical Center, Ben-Gurion University, Beer Sheva 84105, Israel</aff><aff id="af2-jcm-13-06568"><label>2</label>Medical School for International Health, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva 84105, Israel</aff><aff id="af3-jcm-13-06568"><label>3</label>Thoracic Cancer Unit, Cancer Division, Rambam Health Care Campus, Haifa 31096, Israel</aff><aff id="af4-jcm-13-06568"><label>4</label>Lung Oncology Service, Division of Oncology, Meir Medical Center, Kfar Saba 44281, Israel</aff><aff id="af5-jcm-13-06568"><label>5</label>Ichilov Medical Center, Tel-Aviv 64239, Israel</aff><aff id="af6-jcm-13-06568"><label>6</label>Assuta Medical Center, Ashdod 77600, Israel</aff><aff id="af7-jcm-13-06568"><label>7</label>Linn Medical Center, Haifa 35254, Israel</aff><aff id="af8-jcm-13-06568"><label>8</label>Hillel Yaffee Medical Center, Hadera 38203, Israel</aff><aff id="af9-jcm-13-06568"><label>9</label>Department of Pathology, Carmel Medical Center, Haifa 34362, Israel</aff><aff id="af10-jcm-13-06568"><label>10</label>Department of Thoracic Surgery, Carmel Medical Center, Haifa 34362, Israel</aff><aff id="af11-jcm-13-06568"><label>11</label>Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 35254, Israel</aff><aff id="af12-jcm-13-06568"><label>12</label>Division of Thoracic and Esophageal Surgery the Cardiovascular Center, Tzafon Medical Center, Poriya 15208, Israel</aff><aff id="af13-jcm-13-06568"><label>13</label>Department of Oncology, Bnai-Zion Medical Center, Haifa 31048, Israel</aff><author-notes><corresp id="c1-jcm-13-06568"><label>*</label>Correspondence: <email>walid.shalata@gmail.com</email> (W.S.); <email>abed.agbarya@b-zion.org.il</email> (A.A.)</corresp><fn id="fn1-jcm-13-06568"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>31</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>11</month><year>2024</year></pub-date><volume>13</volume><issue>21</issue><issue-id pub-id-type="pmc-issue-id">474661</issue-id><elocation-id>6568</elocation-id><history><date date-type="received"><day>28</day><month>9</month><year>2024</year></date><date date-type="rev-recd"><day>19</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>30</day><month>10</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>31</day><month>10</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>09</day><month>11</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-11-14 06:25:35.803"><day>14</day><month>11</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jcm-13-06568.pdf"/><abstract><p><bold>Background:</bold> Lung cancer is among the most prevalent and serious forms of cancer, characterized by an allogenic phenotype that presents significant therapeutic challenges. <bold>Materials and Methods:</bold> We analyzed medical records from January 2022 to August 2023, focusing on individuals aged 18 and older diagnosed with resectable NSCLC who received neoadjuvant chemo-immunotherapy prior to surgical intervention. <bold>Results:</bold> The cohort comprised 56 patients, predominantly smokers (95%) and male (74%), with 80% presenting the disease at stage III. Of the participants, 44 underwent surgery, with 95% receiving lobar resection. Clinical assessments via PET-CT imaging revealed an 86% rate of response or disease stabilization, while pathological evaluations showed complete and major pathological responses in 61% of cases. <bold>Conclusions:</bold> This real-world data supports the safety and efficacy of incorporating immune checkpoint inhibitors in the neoadjuvant treatment of NSCLC, followed by surgical resection.</p></abstract><kwd-group><kwd>neoadjuvant</kwd><kwd>chemotherapy</kwd><kwd>immunotherapy</kwd><kwd>non-small cell lung cancer</kwd><kwd>resection surgery</kwd><kwd>real-world clinical outcomes</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-jcm-13-06568"><title>1. Introduction</title><p>Lung cancer is one of the most commonly diagnosed malignancies worldwide [<xref rid="B1-jcm-13-06568" ref-type="bibr">1</xref>,<xref rid="B2-jcm-13-06568" ref-type="bibr">2</xref>]. In the United States, 238,340 new cases of lung cancer were documented, and 127,070 deaths were reported, showing the high morbidity and mortality of this disease [<xref rid="B3-jcm-13-06568" ref-type="bibr">3</xref>]. More than two-thirds of the cases are diagnosed in individuals over the age of 65&#8211;70, while roughly up to 5% are diagnosed in individuals under 40&#8211;45 years old. The heightened morbidity and mortality rates associated with NSCLC arise from its frequent diagnosis at progressive stages. Nearly 65&#8211;70% of patients are diagnosed in advanced stages (III/IV) [<xref rid="B4-jcm-13-06568" ref-type="bibr">4</xref>,<xref rid="B5-jcm-13-06568" ref-type="bibr">5</xref>,<xref rid="B6-jcm-13-06568" ref-type="bibr">6</xref>,<xref rid="B7-jcm-13-06568" ref-type="bibr">7</xref>]. This late detection at an advanced stage of an aggressive tumor, with a variety of phenotypes and acquired resistance to treatment, contributes to the poor prognosis of lung cancer in the majority of cases [<xref rid="B3-jcm-13-06568" ref-type="bibr">3</xref>,<xref rid="B4-jcm-13-06568" ref-type="bibr">4</xref>].</p><p>Lung cancer is histologically divided into small cell lung cancer, which comprises approximately 15&#8211;20% of cases, and non-small cell lung cancer (NSCLC), which accounts for almost 80&#8211;85% of cases [<xref rid="B4-jcm-13-06568" ref-type="bibr">4</xref>,<xref rid="B5-jcm-13-06568" ref-type="bibr">5</xref>,<xref rid="B6-jcm-13-06568" ref-type="bibr">6</xref>,<xref rid="B7-jcm-13-06568" ref-type="bibr">7</xref>]. Diagnosis of NSCLC is further subtyped into three main categories: adenocarcinoma (45&#8211;50% of cases), large-cell carcinoma (10&#8211;15% of cases), squamous cell carcinoma (30&#8211;35% of cases), and others (almost 5% of cases) [<xref rid="B4-jcm-13-06568" ref-type="bibr">4</xref>]. The TNM system classifies and categorizes different stages of the disease [<xref rid="B4-jcm-13-06568" ref-type="bibr">4</xref>]. NSCLC treatment is contingent upon the cancer stage and the patient&#8217;s health. Understanding staging is crucial for determining whether tumor removal is viable. Tumors at stages I and II, which are diagnosed in almost 32% of non-metastatic resectable lung cancer patients, signify a localized disease. These early stages are usually eligible for resection without metastatic concerns, while stages IIIC and IV preclude resection. Stage IIIA presents a unique situation: T3N0M0 tumors are resectable, but T3N2M0 tumors are not [<xref rid="B3-jcm-13-06568" ref-type="bibr">3</xref>,<xref rid="B5-jcm-13-06568" ref-type="bibr">5</xref>,<xref rid="B6-jcm-13-06568" ref-type="bibr">6</xref>]. The 5-year survival rate for clinical stage IA1 and IIB were reported to be 92% and 53%, respectively [<xref rid="B5-jcm-13-06568" ref-type="bibr">5</xref>,<xref rid="B6-jcm-13-06568" ref-type="bibr">6</xref>]. However, for locally advanced stage III lung cancer, which accounts for 25% of the patients, the 5-year survival rate range is 13&#8211;36% [<xref rid="B5-jcm-13-06568" ref-type="bibr">5</xref>,<xref rid="B6-jcm-13-06568" ref-type="bibr">6</xref>]. Among 70% of resectable stage IB-IIIA patients, recurrence was observed both loco-regionally and distantly (33% and 67%, respectively) at a median follow-up of 4.5 years [<xref rid="B8-jcm-13-06568" ref-type="bibr">8</xref>,<xref rid="B9-jcm-13-06568" ref-type="bibr">9</xref>].</p><p>Systemic treatment strategies for resectable NSCLC follow three main approaches. The preoperative approach involves the administration of neoadjuvant systemic therapy prior to surgery. The postoperative approach involves applying surgery first and then systemic therapy. The third approach of perioperative therapy combines both pre and postoperative modalities, i.e., systemic therapy, followed by surgery and, later, another round of systemic therapy [<xref rid="B2-jcm-13-06568" ref-type="bibr">2</xref>,<xref rid="B10-jcm-13-06568" ref-type="bibr">10</xref>]. Immunotherapy consensus for early-stage NSCLC patients has recently been published [<xref rid="B11-jcm-13-06568" ref-type="bibr">11</xref>]. Neoadjuvant chemotherapy administered to NSCLC patients was shown to have improved progression-free survival (PFS) by the addition of an immunotherapeutic agent, nivolumab, which is an immune checkpoint inhibitor. Phase I/II and phase III clinical trials NADIM II and Checkmate 816, respectively, demonstrated the effectiveness of this combination therapy [<xref rid="B2-jcm-13-06568" ref-type="bibr">2</xref>,<xref rid="B10-jcm-13-06568" ref-type="bibr">10</xref>,<xref rid="B12-jcm-13-06568" ref-type="bibr">12</xref>]. The impressive results of the phase III Checkmate 816 trial have made a revolution in the treatment of resectable disease NSCLC, and neoadjuvant chemotherapy/immunotherapy (CT/IO) has become a crucial part of the multi-disciplinary treatment of this disease [<xref rid="B13-jcm-13-06568" ref-type="bibr">13</xref>].</p><p>The goal of adjuvant therapy is to minimize the risk of relapse by eradicating minimal residual disease [<xref rid="B14-jcm-13-06568" ref-type="bibr">14</xref>]. Patients with completely resected stage IB-IIIA NSCLC disease had documented recurrence in 33% of cases (out of 831 patients in France, Germany, and the UK). A total of 68% of them had distant metastasis involvement [<xref rid="B15-jcm-13-06568" ref-type="bibr">15</xref>,<xref rid="B16-jcm-13-06568" ref-type="bibr">16</xref>]. The risk of distant metastases was higher than local and regional risk, indicating the need for earlier improved systemic control, such as preoperative neoadjuvant effective therapy [<xref rid="B17-jcm-13-06568" ref-type="bibr">17</xref>]. Lung cancer disease was shown to have a low response rate to standard of care chemotherapy and radiation in addition to challenging treatment for metastases [<xref rid="B4-jcm-13-06568" ref-type="bibr">4</xref>,<xref rid="B18-jcm-13-06568" ref-type="bibr">18</xref>]. Adjuvant chemotherapy has increased the overall survival rate by 5% [<xref rid="B13-jcm-13-06568" ref-type="bibr">13</xref>]. However, an NSCLC Meta-analysis Collaborative Group publication on neoadjuvant chemotherapy found that it led to a 5% increase in 5-year survival benefit [<xref rid="B19-jcm-13-06568" ref-type="bibr">19</xref>]. These clinical outcomes have called for the development of better adjuvant treatments.</p><p>Clinical trials KEYNOTE 91 and IMpower 010 reported novel treatment approaches by the administration of immunotherapy [<xref rid="B20-jcm-13-06568" ref-type="bibr">20</xref>,<xref rid="B21-jcm-13-06568" ref-type="bibr">21</xref>,<xref rid="B22-jcm-13-06568" ref-type="bibr">22</xref>]. Standard of care treatment for patients diagnosed with metastatic NSCLC incorporates immune checkpoint inhibitors (ICIs) [<xref rid="B7-jcm-13-06568" ref-type="bibr">7</xref>]. Nivolumab, an immune checkpoint inhibitor, blocks PD-L1, a protein that is expressed by tumor cells, thus enabling T cells to kill the cancer cells [<xref rid="B23-jcm-13-06568" ref-type="bibr">23</xref>]. Nivolumab was approved by the Food and Drug Administration in 2022 for adult NSCLC patients as part of a neoadjuvant setting in combination with platinum-doublet chemotherapy [<xref rid="B7-jcm-13-06568" ref-type="bibr">7</xref>]. ICIs administered both at neoadjuvant and adjuvant venues display their efficient mode of action by showing better clinical outcomes than without immunotherapy [<xref rid="B7-jcm-13-06568" ref-type="bibr">7</xref>]. Neoadjuvant immunotherapy triggers a T cell anti-tumor response, aiming to reduce its size before surgery [<xref rid="B7-jcm-13-06568" ref-type="bibr">7</xref>,<xref rid="B10-jcm-13-06568" ref-type="bibr">10</xref>]. This may lead to resection surgery of a smaller magnitude, i.e., lobectomy vs. pneumonectomy. In addition, the pathologic response evaluates the neoadjuvant treatment on tissue removed during the operation [<xref rid="B14-jcm-13-06568" ref-type="bibr">14</xref>]. The objective of adjuvant immunotherapy is to eliminate undetectable &#8220;micro metastatic&#8221; residual tumor cells that may exist in lymph nodes, blood vessels, or lymphatic vessels after surgery [<xref rid="B10-jcm-13-06568" ref-type="bibr">10</xref>].</p><p>In the perioperative approach, the role of adjuvant therapy is to prevent recurrence by inducing an anti-metastatic environment [<xref rid="B7-jcm-13-06568" ref-type="bibr">7</xref>]. The KEYNOTE-671 clinical trial results describe pembrolizumab administration in a perioperative setting, both as a neoadjuvant agent combined with chemotherapy and as an adjuvant agent for early NSCLC [<xref rid="B24-jcm-13-06568" ref-type="bibr">24</xref>]. This potent immune checkpoint blocker had improved event-free survival and pathological complete response (pCR) in comparison to the neoadjuvant therapy modality.</p><p>The aim of the study was to check the efficacy of the combination of neoadjuvant therapy on the major pathological response (MPR), which is defined as less than 10% residual viable tumor after neoadjuvant therapy, and pCR, defined as no viable residual tumor.</p></sec><sec id="sec2-jcm-13-06568"><title>2. Materials and Methods</title><sec id="sec2dot1-jcm-13-06568"><title>2.1. Study Design</title><p>This is a real-world retrospective multicenter observational study. Fifty-six NSCLC patients&#8217; data, retrieved from medical records files of nine medical centers in Israel (Soroka Medical Center, Rambam Health Care Campus, Meir Medical Center, Ichilov Medical Center, Assuta Medical Center, Linn Medical Center, Hillel Yaffee Medical Center, Carmel Medical Center, and Bnai-Zion Medical Center) composed the study cohort.</p></sec><sec id="sec2dot2-jcm-13-06568"><title>2.2. Patients Enrolled</title><p>Inclusion criteria were 18 years of age or older, the patients being diagnosed with lung cancer NSCLC in early stages (IB-IIIA), and Eastern Cooperative Oncology Group (ECOG) performance-status scores of 0 to 4 (on a 4-point scale, with higher scores indicating increasing disability). Each of the studied patients was presented to and discussed with a multidisciplinary medical team when admitted to the medical centers&#8217; oncology institute as per the standard protocol. This team included a medical oncologist, a thoracic surgeon, a pulmonologist, a pathologist, an imaging physician, a nuclear medicine physician, and a radiation oncologist. This multidisciplinary team evaluated the patient&#8217;s status, pathology findings, and imaging reports, after which each patient was assigned a primary physician, an oncology specialist responsible for the treatment plan. The patients received a neoadjuvant treatment of combined chemotherapy and immunotherapy with nivolumab, followed by resection surgery. The patients included in the study had not received any previous systemic therapy for any other oncologic disease.</p><p>The exclusion criteria comprised other treatment regimens and the presence of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations within the tumor.</p><p>Each institutional review board (IRB) approved the study. The IRB waived patients&#8217; consent due to the retrospective nature of the study.</p></sec><sec id="sec2dot3-jcm-13-06568"><title>2.3. Treatment Administered</title><p>The planned systemic treatment consisted of platinum-based chemotherapy with nivolumab 360 mg in 3-week intervals for up to 3 cycles in total.</p><sec id="sec2dot3dot1-jcm-13-06568"><title>2.3.1. Non-Squamous Lung Cancer Patients Received 3 Cycles of Chemotherapy of the Physician&#8217;s Choice</title><p>Cisplatin (75 mg per square meter of body surface area) or carboplatin (area under the concentration&#8211;time curve, 4&#8211;5 mg per milliliter per minute, depending on the performance status), plus pemetrexed (500 mg per square meter), plus nivolumab at a fixed dose of 360 mg every three weeks for a total of three cycles. Prior to pemetrexed treatment, premedication of folic acid, vitamin B12, and glucocorticoids was administered to all patients.</p></sec><sec id="sec2dot3dot2-jcm-13-06568"><title>2.3.2. Squamous Cell Carcinoma Lung Cancer Patients Received 3 Cycles of Chemotherapy of the Physician&#8217;s Choice</title><p>Cisplatin (75 mg per square meter of body surface area) or carboplatin (area under the concentration&#8211;time curve, 6.5 or 4 mg per milliliter per minute, depending on the performance status), plus paclitaxel (175 mg per square meter) or gemcitabine (1000 mg per square meter, on days 1 and 8) plus nivolumab at a fixed dose of 360 mg every three weeks for a total of three cycles.</p></sec></sec><sec id="sec2dot4-jcm-13-06568"><title>2.4. Surgery</title><p>All patients underwent a positron emission tomography-computed tomography (PET-CT) imaging for disease restaging purposes 3 weeks after the last dose of neoadjuvant treatment. The multidisciplinary team held a discussion prior to the decision for surgery. The Response Evaluation Criteria in Solid Tumors (RECIST) served for disease evaluation by the treating physician [<xref rid="B25-jcm-13-06568" ref-type="bibr">25</xref>]. Surgery was performed 4&#8211;8 weeks after the last dose of neoadjuvant therapy cycles.</p><p>A board-certified thoracic surgeon performed all of the surgeries in a minimally invasive fashion. Standard surgery included lobar resection with mediastinal lymph node dissection. Patients&#8217; admission either to the intensive care unit or to the thoracic surgery unit following the surgery depended on the complexity of the procedure and the hospital protocols. Two weeks after discharge, the thoracic surgery clinic followed up the patients. Follow-ups continued both by the thoracic surgeon and by the oncologist.</p></sec><sec id="sec2dot5-jcm-13-06568"><title>2.5. Molecular Profiling</title><p>Next-generation sequencing (NGS) genetic testing was performed on biopsy samples for the following oncogenes: epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and ROS proto-oncogene 1 (ROS-1). Also, programmed death ligand 1 (PD-L1), microsatellite instability, and tumor burden were evaluated.</p><p>Immunohistochemistry assessed PD-L1 protein expression. Tumor proportion score (TPS) calculated the percentage of viable tumors showing membrane staining [<xref rid="B26-jcm-13-06568" ref-type="bibr">26</xref>].</p></sec><sec id="sec2dot6-jcm-13-06568"><title>2.6. Data Analysis</title><p>Descriptive statistics were used to calculate frequency (<italic toggle="yes">n</italic>) and percentage for all the parameters of the study. The median and range present the age, follow-up, and days in hospital variables. Fisher&#8217;s exact test was used to assess the association between PD-L1 status and the response to treatment.</p></sec></sec><sec sec-type="results" id="sec3-jcm-13-06568"><title>3. Results</title><sec id="sec3dot1-jcm-13-06568"><title>3.1. Patient Characteristics</title><p>Fifty-six patients were included in the study (<xref rid="jcm-13-06568-t001" ref-type="table">Table 1</xref>). The median follow-up duration was 10 months (range 3&#8211;17 m). The median age of the study cohort participants was 65 years old, and 74% were male. A total of 70% of patients reported current smoking.</p><p>A total of 51% of lung cancer tumors had a histological type of adenocarcinoma. Stage III disease had an 80% prevalence in the study cohort.</p><p>All samples underwent molecular profiling. Analysis of oncogenes ALK, ROS, and EGFR were negative. PD-L1 analysis was performed in 48 patients, and 70% scored &gt; 1%. Other co-mutations detected were KRAS, STK11, p53, and BRCA.</p></sec><sec id="sec3dot2-jcm-13-06568"><title>3.2. Treatment</title><sec><title>Neoadjuvant Therapy</title><p>Taxol<sup>&#174;</sup> (paclitaxel) and Alimta<sup>&#174;</sup> (pemetrexed) are the most commonly administered platinum-based drugs, given to 48% and 46% of cases, respectively (<xref rid="jcm-13-06568-t002" ref-type="table">Table 2</xref>).</p><p>Twice as many patients reported adverse events of any grade following chemotherapy (<italic toggle="yes">n</italic> = 38) than by immunotherapy (<italic toggle="yes">n</italic> = 17) (<xref rid="jcm-13-06568-t003" ref-type="table">Table 3</xref>). Most adverse events were described as grades 1, 2. Moreover, three patients needed to discontinue the treatments.</p></sec></sec><sec id="sec3dot3-jcm-13-06568"><title>3.3. Response to Treatment</title><p>Post-treatment staging was performed using PET-CT. Response to treatment was detected in forty (72%) patients, while tumor progression was evident in eight (14%) cases (<xref rid="jcm-13-06568-t004" ref-type="table">Table 4</xref>). All the non-responders were evaluated as disease progression to either stage IIIB (<italic toggle="yes">n</italic> = 5) or non-operable stage IIIA (<italic toggle="yes">n</italic> = 3). These patients expressed a progressive disease as local progression, but without distant metastasis. Four out of forty-eight responders were not operated due to patients&#8217; refusal and loss of follow-up. Among the forty-four operated patients, pathological complete response was found in sixteen (36.4%), major pathological response was found in twenty-seven (61.4%), and partial pathological response in seventeen (38.6%) (mPR is calculated including the pCR results) (<xref rid="jcm-13-06568-t004" ref-type="table">Table 4</xref> and <xref rid="jcm-13-06568-f001" ref-type="fig">Figure 1</xref>). There are no statistical differences in the response to treatment rate according to the type of histology, TMB, and gender (<italic toggle="yes">p</italic> = 0.68, <italic toggle="yes">p</italic> = 0.67, and <italic toggle="yes">p</italic> = 0.67, respectively).</p></sec><sec id="sec3dot4-jcm-13-06568"><title>3.4. Surgery Results</title><p>Forty-four of the patients&#8217; cohort medical records files documented surgery data (<xref rid="jcm-13-06568-t004" ref-type="table">Table 4</xref>) (four patients refused surgery for personal reasons). Minimally invasive thoracoscopic surgery was performed in forty-two (95%) cases. Lobar resection was performed in forty-three patients (98%), and pneumonectomy was performed in one patient (2%). All tumors were resected with an appropriate margin (R0). Post-surgery complications were recorded in five (11%) patients, three of them had prolonged air leak (6%), one had pneumonia (2%), and one had surgical site infection (2%).</p><p>The association between PD-L1 status and the treatment response was analyzed using Fisher&#8217;s exact test, comparing the rates of the responders (<italic toggle="yes">n</italic> = 48) and non-responders (<italic toggle="yes">n</italic> = 8) in the current study. A total of 17% of responders and 75% of non-responders presented a negative PD-L1 status (<italic toggle="yes">p</italic>-value = 0.0019). Conversely, 69% of responders and 12.5% of non-responders expressed a positive PD-L1 status (<italic toggle="yes">p</italic>-value = 0.004). Of note, 14% of responders and 12.5% of non-responders had unknown PD-L1 status. These findings underscore the significance of PD-L1 status as a predictive biomarker for treatment response, emphasizing its potential utility in guiding therapeutic decisions for patients undergoing immunotherapy. Descriptive statistics in terms of median, percentages, and ranges were calculated for all parameters in the study. Median and ranges were calculated for age, follow-up time, and days in hospital variables. Fisher&#8217;s exact test was performed to test the association between smoking status, histology, gender, PD-L1, and TMB according to the response to treatment rate. A <italic toggle="yes">p</italic> &lt; 0.05 was considered significant (<xref rid="jcm-13-06568-t005" ref-type="table">Table 5</xref>).</p></sec></sec><sec sec-type="discussion" id="sec4-jcm-13-06568"><title>4. Discussion</title><p>Lung cancer is the leading cause of cancer-related deaths globally, claiming an estimated 1.8 million lives in 2020. Traditionally, the standard treatment for resectable NSCLC involved lobectomy followed by systemic adjuvant therapy. However, recent research has highlighted the benefits of neoadjuvant combination therapy (chemo-immunotherapy), ushering in a new perspective. Neoadjuvant treatment presents an alternative avenue to enhance survival rates in patients with resectable NSCLC. This approach offers several potential advantages, including tumor downstaging and early management of micrometastases, facilitating complete resection and improving tolerability [<xref rid="B27-jcm-13-06568" ref-type="bibr">27</xref>,<xref rid="B28-jcm-13-06568" ref-type="bibr">28</xref>].</p><p>The present retrospective multicentric study investigated patients diagnosed with advanced but resectable NSCLC. The present research aimed to assess the efficacy of the combination therapy, i.e., chemo-immunotherapy, in real-world data. Treatment of early-stage NSCLC is complex and involves several modalities due to a variety of factors, such as genetic mutations and other clinical biomarkers [<xref rid="B29-jcm-13-06568" ref-type="bibr">29</xref>].</p><p>Following major clinical trials and approval by the FDA, the NCCN guidelines [Version 1.2024] for non-small cell lung cancer recommend perioperative systemic therapy for patients who are candidates for immune checkpoint inhibitors. The NCCN guidelines provide neoadjuvant and adjuvant updates on an ongoing basis [<xref rid="B30-jcm-13-06568" ref-type="bibr">30</xref>,<xref rid="B31-jcm-13-06568" ref-type="bibr">31</xref>]. Nivolumab and platinum-doublet chemotherapy are suggested for neoadjuvant modality. Pembrolizumab and cisplatin-based doublet chemotherapy for 4 cycles, followed by surgery and adjuvant pembrolizumab every 3 weeks for up to 13 cycles [<xref rid="B30-jcm-13-06568" ref-type="bibr">30</xref>,<xref rid="B31-jcm-13-06568" ref-type="bibr">31</xref>].</p><p>Early stages of NSCLC are treated with a pre-surgery approach, resection, and post-operative therapy. The CheckMate 77T and KEYNOTE 671 trials [<xref rid="B24-jcm-13-06568" ref-type="bibr">24</xref>] reported that perioperative tri-phasic treatment improved survival benefits. The KEYNOTE 671 clinical trial included a multimodality approach of both neoadjuvant and adjuvant therapies. These treatments used immune checkpoint inhibitor pembrolizumab and provided more benefits than a single modality approach [<xref rid="B24-jcm-13-06568" ref-type="bibr">24</xref>]. Immunotherapy reached wide international consensus for NSCLC. The addition of immunotherapy, e.g., nivolumab as an agent in neoadjuvant treatment along with platinum-based chemotherapy, to NSCLC patients presented in the current study is in line with the published results of the clinical trials [<xref rid="B12-jcm-13-06568" ref-type="bibr">12</xref>,<xref rid="B32-jcm-13-06568" ref-type="bibr">32</xref>]. The real-world outcomes of nine medical centers in Israel demonstrated a 36% pathological complete response comparable to NADIM II trial results from hospitals in Spain, which achieved a 37% pathological complete response. Moreover, the sample size of the study cohort was similar: 56 patients were included in the Israeli study and 57 were found eligible in Spain [<xref rid="B12-jcm-13-06568" ref-type="bibr">12</xref>].</p><p>We observed higher rates of partial clinical responses (36%) and major pathological responses (25%) compared to those reported in clinical trials. This difference may be attributed to the fact that 82% of our patients were in stages IIB and IIIA. Additionally, over 70% of our patients tested positive for PD-L1, which is known to be a surrogate marker for a better response to immunotherapy. This is higher than the 55&#8211;60% positivity rates typically reported in clinical trials. Furthermore, 70% of our patients were current smokers, a group known to generally have better responses to immunotherapy compared to former or never-smokers. A systematic review and meta-analysis support this, showing that overall response rates to immunotherapy were significantly higher in current and former smokers compared to never-smokers (36% vs. 26% vs. 14%; <italic toggle="yes">p</italic> = 0.02), with even greater differences among patients with PD-L1 tumor proportion score (TPS) &#8805; 50% (current smokers 58% vs. never-smokers 19%; <italic toggle="yes">p</italic> = 0.03) [<xref rid="B32-jcm-13-06568" ref-type="bibr">32</xref>].</p><p>A recurrence rate of 23.6% has been reported for patients with pathologic complete response after neoadjuvant therapy for locally advanced NSCLC [<xref rid="B17-jcm-13-06568" ref-type="bibr">17</xref>]. Pathologic complete response is observed upon not finding viable tumor cells at the primary tumor site or lymph nodes [<xref rid="B33-jcm-13-06568" ref-type="bibr">33</xref>]. Provencio et al. reported treatment of stage III NSCLC with a perioperative approach, which included a neoadjuvant step of nivolumab and platinum-based chemotherapy followed by surgery and an adjuvant therapy of nivolumab for 6 months [<xref rid="B12-jcm-13-06568" ref-type="bibr">12</xref>]. This clinical trial (NADIM II) resulted in 37% of patients presenting a pathological complete response and longer survival than chemotherapy. That study showed evidence of the synergistic effect of immunotherapy combined with chemotherapy [<xref rid="B12-jcm-13-06568" ref-type="bibr">12</xref>].</p><p>Currently, there are four main therapies that may be utilized as neoadjuvant or perioperative treatments: pembrolizumab from the KEYNOTE-671 trial [<xref rid="B24-jcm-13-06568" ref-type="bibr">24</xref>], nivolumab from the CheckMate 816 trial [<xref rid="B13-jcm-13-06568" ref-type="bibr">13</xref>], toripalimab from the Neotorch trial [<xref rid="B33-jcm-13-06568" ref-type="bibr">33</xref>], and durvalumab from the AEGEAN trial. Several notable differences emerge upon comparing the current study results with findings from the other four main trials assessing the efficacy of neoadjuvant chemo-immunotherapy (<xref rid="jcm-13-06568-t006" ref-type="table">Table 6</xref>). The present study observed a pathologic complete response (pCR) rate of 36%. Contrarily, the CheckMate 816 trial, which administered chemotherapy plus nivolumab for three cycles, reported a pCR rate of 24%. The AEGEAN trial, employing chemotherapy plus durvalumab for four cycles, reported a pCR rate of 17.2%. Similarly, the KEYNOTE-671 trial, utilizing chemotherapy plus pembrolizumab for four cycles, reported a pCR rate of 18.1%. Notably, the Neotorch trial, combining chemotherapy plus toripalimab for three cycles, reported a pCR rate of 24.8%. Regarding the rate of major pathologic response (MPR), the present study reported a high rate of 61%. In comparison, the CheckMate 816 trial reported a MPR rate of 36.9%, the AEGEAN trial reported a rate of 33.3%, the KEYNOTE-671 trial reported a rate of 30.2%, and the Neotorch trial reported a rate of 48.5%.</p><p>In terms of the incidence of grade &#8805; 3 adverse events related to immunotherapy, the current study reported a rate of 12%. In contrast, the Neotorch trial reported a significantly higher rate of 63.4% adverse events. Nevertheless, 0.5% of fatal adverse events relate to toripalimab administration. The CheckMate 816 trial reported a rate of 33.5% adverse events; however, without treatment-related deaths. The AEGEAN trial reported a rate of 42.4% adverse events, with 5.7% of fatal adverse events related to durvalumab administration. The KEYNOTE-671 trial reported a rate of 12.6% adverse events, with 1% death attributed to adverse events. In the current study, 5.17% of the cases discontinued the treatment due to adverse events. This rate was lower compared to the AEGEAN trial (12%), the Neotorch trial (9.4%), the KEYNOTE-671 trial (12.6%), and the CheckMate 816 trial (10.2%). In addition, in our study, the rate of treatment discontinuation was 5.17%, which is much lower than the one observed in clinical trials (10&#8211;12%). This reduced rate may be attributed to the clinical experience of our treatment team and their heightened awareness of the need for close monitoring gained through extensive use of immunotherapy and chemo-immunotherapy. Promptly diagnosing and effectively managing adverse events likely contributed to better patient outcomes and reduced the need for discontinuation.</p><p>The limitations of the current study are attributed to the retrospective and multicenter nature of the investigations. Medical records file collection showed that out of 56 patients eligible as per inclusion criteria, 44 had undergone surgery procedures, which reduced the sample size of the study cohort. Another limitation is that the majority of the study population consisted of stage II and III patients, without the inclusion of stage I patients. This could potentially impact the results of the study, considering that patients with more advanced diseases may derive greater benefit from such an approach. Another limitation is that the study is retrospective. Retrospective studies rely on data collected from past records, which may introduce biases or limitations in data collection and analysis. Another limitation of this study is the short observation period, which hinders the accurate calculation of event-free survival (EFS). A limited timeframe may not capture the full spectrum of disease progression, potentially leading to an underestimation of EFS. Consequently, the findings may not fully reflect the long-term efficacy of the treatment being assessed.</p><p>Future directions in lung cancer treatment research could comprise molecular assays developed for biomarkers as predictors of specific targeted therapies encompassing all stages of NSCLC.</p></sec><sec sec-type="conclusions" id="sec5-jcm-13-06568"><title>5. Conclusions</title><p>The current study demonstrates the advantages of neoadjuvant chemo-immunotherapy for NSCLC patients with resectable disease. These findings align with a recently published clinical trial report, reinforcing the efficacy of neoadjuvant chemo-immunotherapy followed by surgery. Importantly, the approach was found to be safe and feasible, with no significant complications reported.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, W.S. and A.A.; methodology, W.S., S.D., N.M.R., S.S., W.K., I.T., Y.D., O.K., Y.R., E.S., D.L.F., R.G., O.W., K.B. and A.A.; software, W.S., S.D., N.M.R., S.S., W.K., I.T., Y.D., O.K., Y.R., E.S., D.L.F., R.G., O.W., K.B. and A.A.; validation, W.S., S.D., N.M.R., S.S., W.K., I.T., Y.D., O.K., Y.R., E.S., D.L.F., R.G., O.W., K.B. and A.A.; formal analysis, W.S. and A.A.; investigation, W.S., S.D., N.M.R., S.S., W.K., I.T., Y.D., O.K., Y.R., E.S., D.L.F., R.G., O.W., K.B. and A.A.; resources, W.S., S.D., N.M.R., S.S., W.K., I.T., Y.D., O.K., Y.R., E.S., D.L.F., R.G., O.W., K.B. and A.A.; data curation, W.S., S.D., N.M.R., S.S., W.K., I.T., Y.D., O.K., Y.R., E.S., D.L.F., R.G., O.W., K.B. and A.A.; writing&#8212;original draft preparation, W.S., O.W. and A.A.; writing&#8212;review and editing, W.S., O.W. and A.A.; visualization, W.S., O.W. and A.A.; supervision, W.S., O.W. and A.A.; project administration, W.S., O.W. and A.A.; funding acquisition, W.S. and A.A. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Bnai Zion Medical Center (approval no. 0023-22-BNZ, approval date 30 January 2022).</p></notes><notes><title>Informed Consent Statement</title><p>Patient consent was waived due to the retrospective nature of the study and the collection of data in international registries.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>All data generated or analyzed during this study are included in this article. Further inquiries can be directed to the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-jcm-13-06568"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thai</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Sequist</surname><given-names>L.V.</given-names></name><name name-style="western"><surname>Gainor</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Heist</surname><given-names>R.S.</given-names></name></person-group><article-title>Lung cancer</article-title><source>Lancet</source><year>2021</year><volume>398</volume><fpage>535</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00312-3</pub-id><pub-id pub-id-type="pmid">34273294</pub-id></element-citation></ref><ref id="B2-jcm-13-06568"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>John</surname><given-names>A.O.</given-names></name><name name-style="western"><surname>Ramnath</surname><given-names>N.</given-names></name></person-group><article-title>Neoadjuvant Versus Adjuvant Systemic Therapy for Early-Stage Non-Small Cell Lung Cancer: The Changing Landscape Due to Immunotherapy</article-title><source>Oncologist</source><year>2023</year><volume>28</volume><fpage>752</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1093/oncolo/oyad125</pub-id><pub-id pub-id-type="pmid">37338126</pub-id><pub-id pub-id-type="pmcid">PMC10485299</pub-id></element-citation></ref><ref id="B3-jcm-13-06568"><label>3.</label><element-citation publication-type="gov"><article-title>Surveillance, Epidemiology, and End Results (SEER) Program</article-title><year>2023</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://seer.cancer.gov/" ext-link-type="uri">http://seer.cancer.gov/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-04-04">(accessed on 4 April 2024)</date-in-citation></element-citation></ref><ref id="B4-jcm-13-06568"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nooreldeen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bach</surname><given-names>H.</given-names></name></person-group><article-title>Current and Future Development in Lung Cancer Diagnosis</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>8661</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22168661</pub-id><pub-id pub-id-type="pmid">34445366</pub-id><pub-id pub-id-type="pmcid">PMC8395394</pub-id></element-citation></ref><ref id="B5-jcm-13-06568"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ettinger</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Aisner</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Akerley</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bauman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Chirieac</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>D&#8217;Amico</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Dilling</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Dobelbower</surname><given-names>M.</given-names></name><etal/></person-group><article-title>NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018</article-title><source>J. Natl. Com. Cancer Netw.</source><year>2018</year><volume>16</volume><fpage>807</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.6004/jnccn.2018.0062</pub-id><pub-id pub-id-type="pmid">30006423</pub-id></element-citation></ref><ref id="B6-jcm-13-06568"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldstraw</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chansky</surname><given-names>K.</given-names></name><name name-style="western"><surname>Crowley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rami-Porta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Asamura</surname><given-names>H.</given-names></name><name name-style="western"><surname>Eberhardt</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Nicholson</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Groome</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bolejack</surname><given-names>V.</given-names></name><etal/></person-group><article-title>The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer</article-title><source>J. Thorac. Oncol.</source><year>2016</year><volume>11</volume><fpage>39</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2015.09.009</pub-id><pub-id pub-id-type="pmid">26762738</pub-id></element-citation></ref><ref id="B7-jcm-13-06568"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lazzari</surname><given-names>C.</given-names></name><name name-style="western"><surname>Spagnolo</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Ciappina</surname><given-names>G.</given-names></name><name name-style="western"><surname>Di Pietro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Squeri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Passalacqua</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Marchesi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gregorc</surname><given-names>V.</given-names></name><name name-style="western"><surname>Santarpia</surname><given-names>M.</given-names></name></person-group><article-title>Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives</article-title><source>Curr. Oncol.</source><year>2023</year><volume>30</volume><fpage>3684</fpage><lpage>3696</lpage><pub-id pub-id-type="doi">10.3390/curroncol30040280</pub-id><pub-id pub-id-type="pmid">37185393</pub-id><pub-id pub-id-type="pmcid">PMC10136903</pub-id></element-citation></ref><ref id="B8-jcm-13-06568"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>West</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chirovsky</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lerner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Signorovitch</surname><given-names>J.</given-names></name><name name-style="western"><surname>Samkari</surname><given-names>A.</given-names></name></person-group><article-title>Treatment Patterns and Outcomes in Resected Early-stage Non-small Cell Lung Cancer: An Analysis of the SEER-Medicare Data</article-title><source>Clin. Lung Cancer</source><year>2023</year><volume>24</volume><fpage>260</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1016/j.cllc.2022.12.005</pub-id><pub-id pub-id-type="pmid">36641325</pub-id></element-citation></ref><ref id="B9-jcm-13-06568"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>West</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chirovsky</surname><given-names>D.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kaushiva</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tepsick</surname><given-names>J.</given-names></name><name name-style="western"><surname>Samkari</surname><given-names>A.</given-names></name></person-group><article-title>Clinical and economic impact of recurrence in early-stage non-small-cell lung cancer following complete resection</article-title><source>Future Oncol.</source><year>2023</year><volume>19</volume><fpage>1415</fpage><lpage>1427</lpage><pub-id pub-id-type="doi">10.2217/fon-2023-0024</pub-id><pub-id pub-id-type="pmid">37218514</pub-id></element-citation></ref><ref id="B10-jcm-13-06568"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Versluis</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Long</surname><given-names>G.V.</given-names></name><name name-style="western"><surname>Blank</surname><given-names>C.U.</given-names></name></person-group><article-title>Learning from clinical trials of neoadjuvant checkpoint blockade</article-title><source>Nat. Med.</source><year>2020</year><volume>26</volume><fpage>475</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0829-0</pub-id><pub-id pub-id-type="pmid">32273608</pub-id></element-citation></ref><ref id="B11-jcm-13-06568"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.-N.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dongle</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>International expert consensus on immunotherapy for early-stage non-small cell lung cancer</article-title><source>Transl. Lung Cancer Res.</source><year>2022</year><volume>11</volume><fpage>1742</fpage><lpage>1762</lpage><pub-id pub-id-type="doi">10.21037/tlcr-22-617</pub-id><pub-id pub-id-type="pmid">36248334</pub-id><pub-id pub-id-type="pmcid">PMC9554679</pub-id></element-citation></ref><ref id="B12-jcm-13-06568"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Provencio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nadal</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Larriba</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Mart&#237;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bernab&#233;</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bosch-Barrera</surname><given-names>J.</given-names></name><name name-style="western"><surname>Casal-Rubio</surname><given-names>J.</given-names></name><name name-style="western"><surname>Calvo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Insa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ponce</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer</article-title><source>N. Engl. J. Med.</source><year>2023</year><volume>389</volume><fpage>504</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2215530</pub-id><pub-id pub-id-type="pmid">37379158</pub-id></element-citation></ref><ref id="B13-jcm-13-06568"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forde</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Spicer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Provencio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mitsudomi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Awad</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Felip</surname><given-names>E.</given-names></name><name name-style="western"><surname>Broderick</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Brahmer</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>S.J.</given-names></name><etal/></person-group><article-title>Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer</article-title><source>N. Engl. J. Med.</source><year>2022</year><volume>386</volume><fpage>1973</fpage><lpage>1985</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2202170</pub-id><pub-id pub-id-type="pmid">35403841</pub-id><pub-id pub-id-type="pmcid">PMC9844511</pub-id></element-citation></ref><ref id="B14-jcm-13-06568"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Indini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rijavec</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bareggi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Grossi</surname><given-names>F.</given-names></name></person-group><article-title>Novel treatment strategies for early-stage lung cancer: The oncologist&#8217;s perspective</article-title><source>J. Thorac. Dis.</source><year>2020</year><volume>12</volume><fpage>3390</fpage><lpage>3398</lpage><pub-id pub-id-type="doi">10.21037/jtd.2020.02.46</pub-id><pub-id pub-id-type="pmid">32642264</pub-id><pub-id pub-id-type="pmcid">PMC7330760</pub-id></element-citation></ref><ref id="B15-jcm-13-06568"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chouaid</surname><given-names>C.</given-names></name><name name-style="western"><surname>Danson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Andreas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Siakpere</surname><given-names>O.</given-names></name><name name-style="western"><surname>Benjamin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ehness</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dramard-Goasdoue</surname><given-names>M.-H.</given-names></name><name name-style="western"><surname>Barth</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>H.</given-names></name><name name-style="western"><surname>Potter</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study</article-title><source>Lung Cancer</source><year>2018</year><volume>124</volume><fpage>310</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2018.07.042</pub-id><pub-id pub-id-type="pmid">30119925</pub-id></element-citation></ref><ref id="B16-jcm-13-06568"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>West</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chirovsky</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lerner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Signorovitch</surname><given-names>J.</given-names></name><name name-style="western"><surname>Samkari</surname><given-names>A.</given-names></name></person-group><article-title>Evaluation of disease-free survival as a predictor of overall survival and assessment of real-world burden of disease recurrence in resected early-stage non-small cell lung cancer</article-title><source>J. Manag. Care Spec. Pharm.</source><year>2023</year><volume>29</volume><fpage>749</fpage><lpage>757</lpage><pub-id pub-id-type="doi">10.18553/jmcp.2023.29.7.749</pub-id><pub-id pub-id-type="pmid">37404067</pub-id><pub-id pub-id-type="pmcid">PMC10387987</pub-id></element-citation></ref><ref id="B17-jcm-13-06568"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melek</surname><given-names>H.</given-names></name><name name-style="western"><surname>&#199;etinkaya</surname><given-names>G.</given-names></name><name name-style="western"><surname>&#214;zer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yent&#252;rk</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sevin&#231;</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Bayram</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Gebitekin</surname><given-names>C.</given-names></name></person-group><article-title>Pathological complete response after neoadjuvant/induction treatment: Where is its place in the lung cancer staging system?</article-title><source>Eur. J. Cardiothorac. Surg.</source><year>2019</year><volume>56</volume><fpage>604</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1093/ejcts/ezz044</pub-id><pub-id pub-id-type="pmid">30809654</pub-id></element-citation></ref><ref id="B18-jcm-13-06568"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blandin Knight</surname><given-names>S.</given-names></name><name name-style="western"><surname>Crosbie</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Balata</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chudziak</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hussell</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dive</surname><given-names>C.</given-names></name></person-group><article-title>Progress and prospects of early detection in lung cancer</article-title><source>Open Biol.</source><year>2017</year><volume>7</volume><elocation-id>170070</elocation-id><pub-id pub-id-type="doi">10.1098/rsob.170070</pub-id><pub-id pub-id-type="pmid">28878044</pub-id><pub-id pub-id-type="pmcid">PMC5627048</pub-id></element-citation></ref><ref id="B19-jcm-13-06568"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>NSCLC Meta-analysis Collaborative Group</collab></person-group><article-title>Preoperative chemotherapy for non-small-cell lung cancer: A systematic review and meta-analysis of individual participant data</article-title><source>Lancet</source><year>2014</year><volume>383</volume><fpage>1561</fpage><lpage>1571</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(13)62159-5</pub-id><pub-id pub-id-type="pmid">24576776</pub-id><pub-id pub-id-type="pmcid">PMC4022989</pub-id></element-citation></ref><ref id="B20-jcm-13-06568"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;brien</surname><given-names>M.</given-names></name><name name-style="western"><surname>Paz-Ares</surname><given-names>L.</given-names></name><name name-style="western"><surname>Marreaud</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dafni</surname><given-names>U.</given-names></name><name name-style="western"><surname>Oselin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Havel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Esteban</surname><given-names>E.</given-names></name><name name-style="western"><surname>Isla</surname><given-names>D.</given-names></name><name name-style="western"><surname>Martinez-Marti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Faehling</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): An interim analysis of a randomised, triple-blind, phase 3 trial</article-title><source>Lancet Oncol.</source><year>2022</year><volume>23</volume><fpage>1274</fpage><lpage>1286</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(22)00518-6</pub-id><pub-id pub-id-type="pmid">36108662</pub-id></element-citation></ref><ref id="B21-jcm-13-06568"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halmos</surname><given-names>B.</given-names></name><name name-style="western"><surname>Burke</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kalyvas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vandormael</surname><given-names>K.</given-names></name><name name-style="western"><surname>Frederickson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Piperdi</surname><given-names>B.</given-names></name></person-group><article-title>Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/&#8722;bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison</article-title><source>Lung Cancer</source><year>2021</year><volume>155</volume><fpage>175</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2021.03.020</pub-id><pub-id pub-id-type="pmid">33839603</pub-id></element-citation></ref><ref id="B22-jcm-13-06568"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wakelee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liberman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tsuboi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.-H.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.-N.</given-names></name><name name-style="western"><surname>Dooms</surname><given-names>C.</given-names></name><name name-style="western"><surname>Majem</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eigendorff</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer</article-title><source>N. Engl. J. Med.</source><year>2023</year><volume>389</volume><fpage>491</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2302983</pub-id><pub-id pub-id-type="pmid">37272513</pub-id><pub-id pub-id-type="pmcid">PMC11074923</pub-id></element-citation></ref><ref id="B23-jcm-13-06568"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eisenhauer</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Therasse</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bogaerts</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Sargent</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ford</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dancey</surname><given-names>J.</given-names></name><name name-style="western"><surname>Arbuck</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gwyther</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mooney</surname><given-names>M.</given-names></name><etal/></person-group><article-title>New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)</article-title><source>Eur. J. Cancer</source><year>2009</year><volume>45</volume><fpage>228</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2008.10.026</pub-id><pub-id pub-id-type="pmid">19097774</pub-id></element-citation></ref><ref id="B24-jcm-13-06568"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Marchi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Leal</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>V.D.</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>E.C.A.</given-names></name><name name-style="western"><surname>de Lima</surname><given-names>V.C.C.</given-names></name><name name-style="western"><surname>Reis</surname><given-names>R.M.</given-names></name></person-group><article-title>Reis RM. PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC)</article-title><source>J. Clin. Pathol.</source><year>2021</year><volume>74</volume><fpage>735</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.1136/jclinpath-2020-206832</pub-id><pub-id pub-id-type="pmid">33589532</pub-id></element-citation></ref><ref id="B25-jcm-13-06568"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J.</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Laversanne</surname><given-names>M.</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I.</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bray</surname><given-names>F.</given-names></name></person-group><article-title>Global Cancer Statistics 2020: GLOBOCANEstimates of Incidence Mortality and Worldwide for 36 Cancers in 185 Countries</article-title><source>CA Cancer J. Clin.</source><year>2021</year><volume>71</volume><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id></element-citation></ref><ref id="B26-jcm-13-06568"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shalata</surname><given-names>W.</given-names></name><name name-style="western"><surname>Rabinovich</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Agbarya</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yakobson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dudnik</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Abu Jama</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>A.Y.</given-names></name><name name-style="western"><surname>Shalata</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abu Hamed</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ber</surname><given-names>T.I.</given-names></name><etal/></person-group><article-title>Efficacy of Pembrolizumab vs. Nivolumab Plus Ipilimumab in Metastatic NSCLC in Relation to PD-L1 and TMB Status</article-title><source>Cancers</source><year>2024</year><volume>16</volume><elocation-id>1825</elocation-id><pub-id pub-id-type="doi">10.3390/cancers16101825</pub-id><pub-id pub-id-type="pmid">38791905</pub-id><pub-id pub-id-type="pmcid">PMC11119071</pub-id></element-citation></ref><ref id="B27-jcm-13-06568"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>West</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.Y.</given-names></name></person-group><article-title>Rapid Advances in Resectable Non-Small Cell Lung Cancer: A Narrative Review</article-title><source>JAMA Oncol.</source><year>2024</year><volume>10</volume><fpage>249</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2023.5276</pub-id><pub-id pub-id-type="pmid">38153722</pub-id></element-citation></ref><ref id="B28-jcm-13-06568"><label>28.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>National Comprehensive Cancer Network</collab></person-group><article-title>Non-Small Cell Lung Cancer Guidelines in Oncology. Version 3.2023</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf" ext-link-type="uri">https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-04-04">(accessed on 4 April 2024)</date-in-citation></element-citation></ref><ref id="B29-jcm-13-06568"><label>29.</label><element-citation publication-type="webpage"><article-title>National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology, Non-Small Cell Lung Cancer, Version 3.2024 Perioperative Systemic Therapy</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://crain-platform-precisiononcologynews-prod.s3.amazonaws.com/2024-04/nscl_NCCN%20guidelines.pdf" ext-link-type="uri">https://crain-platform-precisiononcologynews-prod.s3.amazonaws.com/2024-04/nscl_NCCN%20guidelines.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-05-05">(accessed on 5 May 2024)</date-in-citation></element-citation></ref><ref id="B30-jcm-13-06568"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>He</surname><given-names>J.</given-names></name><name name-style="western"><surname>Su</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Q.</given-names></name></person-group><article-title>Impact of Smoking History on Response to Immunotherapy in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis</article-title><source>Front. Oncol.</source><year>2021</year><volume>11</volume><elocation-id>703143</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2021.703143</pub-id><pub-id pub-id-type="pmid">34497760</pub-id><pub-id pub-id-type="pmcid">PMC8419340</pub-id></element-citation></ref><ref id="B31-jcm-13-06568"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Travis</surname><given-names>W.D.</given-names></name><name name-style="western"><surname>Dacic</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wistuba</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sholl</surname><given-names>L.</given-names></name><name name-style="western"><surname>Adusumilli</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bubendorf</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bunn</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cascone</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chaft</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name><etal/></person-group><article-title>IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy</article-title><source>J. Thorac. Oncol.</source><year>2020</year><volume>15</volume><fpage>709</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2020.01.005</pub-id><pub-id pub-id-type="pmid">32004713</pub-id><pub-id pub-id-type="pmcid">PMC8173999</pub-id></element-citation></ref><ref id="B32-jcm-13-06568"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><collab>Neotorch Investigators</collab><name name-style="western"><surname>Fang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial</article-title><source>JAMA</source><year>2024</year><volume>331</volume><fpage>201</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1001/jama.2023.24735</pub-id><pub-id pub-id-type="pmid">38227033</pub-id><pub-id pub-id-type="pmcid">PMC10792477</pub-id></element-citation></ref><ref id="B33-jcm-13-06568"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heymach</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Harpole</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mitsudomi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Taube</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Galffy</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hochmair</surname><given-names>M.</given-names></name><name name-style="western"><surname>Winder</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zukov</surname><given-names>R.</given-names></name><name name-style="western"><surname>Garbaos</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer</article-title><source>N. Engl. J. Med.</source><year>2023</year><volume>389</volume><fpage>1672</fpage><lpage>1684</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2304875</pub-id><pub-id pub-id-type="pmid">37870974</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="jcm-13-06568-f001" orientation="portrait"><label>Figure 1</label><caption><p>Flow diagram of the study summarizing patient selection and key outcomes, including pathological results. Abbreviations: N, number; Pathological complete response, pCR; Major pathological response, MPR; Partial response, PR. * mPR is calculated including the pCR results.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jcm-13-06568-g001.jpg"/></fig><table-wrap position="float" id="jcm-13-06568-t001" orientation="portrait"><object-id pub-id-type="pii">jcm-13-06568-t001_Table 1</object-id><label>Table 1</label><caption><p>Demographic and clinical characteristics of the study population (<italic toggle="yes">n</italic> = 56).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Characteristic</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Frequency (<italic toggle="yes">n</italic>)</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Percentage (%)</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age, (years), median [range]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65 [51&#8211;79]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gender</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Female</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">74</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baseline conditions</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">77</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COPD/IHD</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Smoking habits</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Current</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Past</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Light</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Never</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Follow-up (months), median [range]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 [3&#8211;17]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Histology</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adenocarcinoma</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Squamous cell carcinoma</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Other</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DiseasesStage</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IIB</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IIIA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">62</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IIIB</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Molecular profile of EGFR, ALK, ROS1-performed</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TMB-performed</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSI-performed</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">73</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PD-L1-performed</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Time till results (days), median [range]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 [4&#8211;22]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PD-L1 expression level</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&gt;1%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;1%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Other mutations checked</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KRAS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STK11</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P53</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRCA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: COPD, chronic obstructive pulmonary disease; IHD, ischemic heart disease; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; ROS, ros-proto oncogene1; PD-L1, programmed death ligand 1; TMB, tumor mutational burden; MSI, microsatellite instability; KRAS, Kirsten rat sarcomas viral oncogene; STK, serine/threonine kinase 11; BRCA, breast cancer gene. Notes: PD-L1 score &lt; 1% is considered negative. PD-L1 score &gt; 1% is considered positive.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jcm-13-06568-t002" orientation="portrait"><object-id pub-id-type="pii">jcm-13-06568-t002_Table 2</object-id><label>Table 2</label><caption><p>Treatment: platinum-based chemotherapy used in the study population (<italic toggle="yes">n</italic> = 56).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Platinum-Based Combination</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Patients<break/><italic toggle="yes">n</italic> (%)</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No. of Cycles (No. of Patients, Percentage)</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paclitaxel</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27 (48)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (2 patients, 4%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pemetrexed</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26 (46)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (1 patient, 2%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gemcitabine</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (4)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (40 patients, 70%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Etoposide</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (2)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (13 patients, 23%)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="jcm-13-06568-t003" orientation="portrait"><object-id pub-id-type="pii">jcm-13-06568-t003_Table 3</object-id><label>Table 3</label><caption><p>Treatment reported toxicity and adverse events <italic toggle="yes">n</italic> (%).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Treatment</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Any Grade</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Grades 1, 2</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Grades 3, 4</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chemotherapy, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38 (68%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31 (81%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (18%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunotherapy, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17 (30%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15 (88%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (12%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dose change</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dose interruption</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (5.17%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dose reduction</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1.72%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Discontinuation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (5.17%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adverse events <sup>a</sup></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diarrhea</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (23%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11(84%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (15%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nausea/vomiting</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14 (25%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14 (100%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Weakness</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29 (52%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 (86%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (13%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuropathy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (20%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (82%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (18%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thyroid</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14 (25%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (93%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (7%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Skin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 (21%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 (100%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p>Notes: <sup>a</sup> any grade adverse events rates were calculated as percentage of total cohort <italic toggle="yes">n =</italic> 56. Grades 1, 2 and grades 3, 4 toxicity rates were calculated as percent of the &#8220;any grade&#8221; category.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jcm-13-06568-t004" orientation="portrait"><object-id pub-id-type="pii">jcm-13-06568-t004_Table 4</object-id><label>Table 4</label><caption><p>Clinical description of surgery and response to treatment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Procedure</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Patient Frequency <italic toggle="yes">n</italic>, (Percentage %)</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Surgery</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44 (78%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thoracoscopy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42 (42/44, 95%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Open surgery</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (2/44, 5%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Resection</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lobectomy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43 (98%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pneumonectomy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (2%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Days in hospital, median [range]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 [2&#8211;29]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Complications</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (5/44, 11%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prolong air leak</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (3/44, 6%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pneumonia</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1/44, 2%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Surgical site infection</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1/44, 2%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical response by PET-CT</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Complete response</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (11%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Partial response</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34 (61%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stable disease</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (14%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor progression</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (14%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Surgery</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44 (79%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pathological response</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Complete response</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16 (36.4%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Major pathologic response</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27 (61.4%)</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: PET-CT, positron emission tomography-computed tomography; <italic toggle="yes">n</italic>, number.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jcm-13-06568-t005" orientation="portrait"><object-id pub-id-type="pii">jcm-13-06568-t005_Table 5</object-id><label>Table 5</label><caption><p>The clinical biomarker for response by Fisher&#8217;s exact test.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No Response; <italic toggle="yes">n =</italic> 8</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Response; <italic toggle="yes">n</italic> = 48</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PD-L1 status</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Negative <sup>a</sup></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6/8 (75%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8/48 (17%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0019</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Positive <sup>b</sup></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/8 (12.5%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33/48 (69%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/8 (12.5%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7/48 (14%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Smoking status</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Current and past</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/8 (37.5%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46/48 (95.8%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0003</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Light and never</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5/8 (62.5%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/48 (4.2%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0003</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Histology</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adenocarcinoma</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4/8 (50.0%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25/48 (52.1%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Squamous cell carcinoma</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/8 (25.0%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20/48 (41.7%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Other</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/8 (12.5%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/48 (6.3%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TMB status</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High (over 10 Mut/Mb)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5/8 (62.5%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11/35 (31.4%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.67</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low (under 10 Mut/Mb)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/8 (37.5%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24/35 (68.6%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.67</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gender</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5/8 (62.5%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36/48 (75.0%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.67</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Female</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/8 (37.5%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12/48 (25.0%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.67</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: <italic toggle="yes">n</italic>, number; PD-L1, programmed death-ligand 1; TMB, tumor mutational burden; Mut/Mb, mutations per megabase. Notes: <sup>a</sup> PD-L1 score &lt; 1% is considered negative. <sup>b</sup> PD-L1 score &gt; 1% is considered positive.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jcm-13-06568-t006" orientation="portrait"><object-id pub-id-type="pii">jcm-13-06568-t006_Table 6</object-id><label>Table 6</label><caption><p>Comparing the current study results with findings from other trials.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">pCR Rate (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MPR Rate (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Grade &#8805; 3 AE (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Treatment Discontinuation (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Current study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 (no death)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CheckMate 816</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33.5 (no death)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B13-jcm-13-06568" ref-type="bibr">13</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AEGEAN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42.4 (5.7% death)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B33-jcm-13-06568" ref-type="bibr">33</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KEYNOTE-671</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.6 (1% death)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B24-jcm-13-06568" ref-type="bibr">24</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neotorch</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">63.4 (0.5% death)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B32-jcm-13-06568" ref-type="bibr">32</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: pCR, pathologic complete response; MPR, major pathologic response; AE, adverse events.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>